Want to see SE:NICA full AI Analyst Report?
Nanologica AB (NICA) AI Stock Analysis
Nanologica AB
(Nasdaq OMX AB:NICA)
Mixed financial results with top-line growth but ongoing cash burn, combined with weak technical momentum, are the dominant factors; attractive valuation offers partial offset.
Nanologica AB (NICA) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 54.25M
- Dividend Yield
- ―
- Average Volume (3M)
- 652.95K
- Price to Earnings (P/E)
- 0.5
- Beta (1Y)
- 1.96
- Revenue Growth
- 163.58%
- EPS Growth
- ―
- Country
- Sweden
- Employees
- 72
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
Nanologica AB Business Overview & Revenue Model
Company Description
Nanologica AB (publ), a nanotechnology company, develops, manufactures, and sells nanoporous silica particles for life science industry in China, India, the United State of America, and internationally. It offers NLAB Saga, a new generation silica fo...
How the Company Makes Money
Nanologica makes money primarily by selling its nanostructured silica-based products and related services to customers in pharma and life science workflows. Key revenue streams: 1) Product sales (chromatography media / silica materials): Revenue is g...
Nanologica AB Financial Statement Overview
Summary
Revenue growth and improved equity position are offset by negative gross margins, operating losses, and heavy cash burn.
Income Statement
52NeutralBalance Sheet
68PositiveCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 53.80M | 21.13M | 14.54M | 1.44M | 1.55M | 12.91M |
| Gross Profit | -53.98M | -49.40M | 4.29M | -76.00K | 3.23M | 4.92M |
| EBITDA | -36.71M | -34.55M | -45.17M | -54.97M | -38.36M | -31.13M |
| Net Income | 18.76M | -51.29M | -65.63M | -75.16M | -55.09M | -50.13M |
Balance Sheet | ||||||
| Total Assets | 243.59M | 88.11M | 143.10M | 77.43M | 154.51M | 98.32M |
| Cash, Cash Equivalents and Short-Term Investments | 19.06M | 3.55M | 48.43M | 10.05M | 70.32M | 11.70M |
| Total Debt | 53.63M | 21.47M | 50.94M | 666.00K | 4.69M | 9.79M |
| Total Liabilities | 87.16M | 65.47M | 68.99M | 79.33M | 81.36M | 46.72M |
| Stockholders Equity | 156.43M | 22.64M | 74.11M | -1.90M | 73.16M | 51.60M |
Cash Flow | ||||||
| Free Cash Flow | -58.33M | -40.88M | -81.48M | -56.83M | -53.78M | -53.74M |
| Operating Cash Flow | -56.86M | -39.88M | -80.73M | -35.85M | -45.22M | -46.49M |
| Investing Cash Flow | -5.36M | -1.08M | -742.00K | -20.35M | -7.14M | -7.25M |
| Financing Cash Flow | 23.40M | -3.21M | 120.23M | -4.09M | 111.70M | -1.64M |
Nanologica AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:NICA, the sentiment is Negative. The current price of 0.17 is below the 20-day moving average (MA) of 0.24, below the 50-day MA of 0.31, and below the 200-day MA of 0.44, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 19.73 is Positive, neither overbought nor oversold. The STOCH value of 6.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:NICA.
Nanologica AB Peers Comparison
Overall Rating
SE:CAMX80Outperform
SE:XBRANE53Neutral- SE:NICA53Neutral
SE:NANEXA52Neutral
SE:SPAGO43Neutral
SE:XSPRAY41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SE:CAMX | 80Outperform | SEK 40.76B | 59.09 | 15.54% | ― | <0.01% | -6.75% |
| SE:XBRANE | 53Neutral | SEK 291.57M | -5.90 | -11.52% | ― | -38.80% | -120.18% |
| SE:NICA | 53Neutral | SEK 54.25M | 0.48 | 23.67% | ― | 163.58% | ― |
| SE:NANEXA | 52Neutral | SEK 1.97B | -76.50 | -22.38% | ― | 104.76% | 37.08% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SE:SPAGO | 43Neutral | SEK 32.09M | -0.85 | -106.23% | ― | -97.37% | 25.28% |
| SE:XSPRAY | 41Neutral | SEK 559.52M | -3.06 | -26.00% | ― | ― | 44.46% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:NICA | Nanologica AB | 0.17 | -1.12 | -87.14% | |
| SE:CAMX | Camurus AB | 673.00 | 62.00 | 10.15% | |
| SE:XBRANE | Xbrane Biopharma AB | 14.15 | 3.60 | 34.12% | |
| SE:XSPRAY | Xspray Pharma AB | 11.80 | -12.41 | -51.27% | |
| SE:SPAGO | Spago Nanomedical AB | 0.04 | -0.10 | -72.22% | |
| SE:NANEXA | Nanexa AB | 10.32 | 8.55 | 483.71% |
Nanologica AB Corporate Events
Nanologica Calls EGM to Approve Rights Issue Guarantee Deal
Nanologica AB has called an Extraordinary General Meeting for November 30, 2026, in Stockholm, where shareholders will vote on several key proposals, including a related party transaction, a directed issue of units, and new Articles of Association. T...
Nanologica launches SEK 110.5m rights issue amid strategic shift and new CEO
Nanologica AB has resolved to carry out a partially guaranteed rights issue of units of approximately SEK 110.5 million, with an additional oversubscription option of SEK 10 million, to support a strategic shift toward accelerated commercial growth....
Nanologica Revamps Strategy, Names New CEO and Plans SEK 110.5m Rights Issue
Nanologica AB has unveiled an updated strategy aimed at accelerating commercial growth, broadening its purification and separation offering and shifting its commercial focus toward higher-margin markets in North America and Europe. The company is bui...
Nanologica Boosts Revenue on Syntagon Acquisition Amid CFO Transition
Nanologica AB reported a sharp increase in net sales in the second quarter of 2026 to SEK 24.3 million from SEK 2.3 million a year earlier, and SEK 45.8 million for the half-year, largely driven by the consolidation of Syntagon. Despite the revenue g...
Nanologica Delays Q2 Report Amid Syntagon Integration
Nanologica AB has postponed the publication of its Q2 2026 interim report to 31 August from the previously scheduled 20 August. The delay is due to extended validation work on the consolidated financial statements following the company’s acquis...
Nanologica Names Axel Elner as CFO Ahead of Commercial Expansion
Nanologica AB has appointed Axel Elner as its new chief financial officer, effective 10 November 2026, succeeding Eva Osterman, who leaves the company at the end of August. Elner brings extensive experience from Viaplay Group and Allente Nordic, wher...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026